Experimental drug for rare epilepsy disorders fails to complete trial
NCT ID NCT04378075
First seen Apr 03, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This study tested a drug called vatiquinone in 68 people with mitochondrial disease who have hard-to-control seizures. Participants were randomly assigned to receive either the drug or a placebo for 24 weeks, with an option to continue the drug afterward. The trial was stopped early, so results are limited. The goal was to see if vatiquinone could reduce seizure frequency and hospital stays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG-RESISTANT EPILEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.P.H.P - Hôpital Necker-Enfants Malades - Service de Neurologie pédiatrique
Paris, 75015, France
-
Akron Children's Hospital
Akron, Ohio, 44308, United States
-
Alberta Children's Hospital, University of Calgary
Calgary, T3B 6A8, Canada
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Boston Children Hospital
Boston, Massachusetts, 02115, United States
-
CHU d'Angers - Service de génétique
Angers, 49933, France
-
CHU de Montpellier - Hôpital Gui de Chauliac - Département de neuropédiatrie
Montpellier, 34295, France
-
CHU de Strasbourg - Hôpital de Hautepierre - Service de Neuropédiatrie
Strasbourg, 67200, France
-
Children's National Medical Center - Department Of Neurology
Washington D.C., District of Columbia, 20010, United States
-
Children's of Minnesota
Minneapolis, Minnesota, 55404, United States
-
Great Ormond Street Hospital for Children NHS Foundation Trust
London, WC1N 3JH, United Kingdom
-
Hospital Ruber Internacional, Neurology Department, Epilepsy Program
Madrid, 28034, Spain
-
Hospital Sant Joan de Déu
Barcelona, 08950, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Instytut Pomnik-Centrum Zdrowia Dziecka, Centrum Wsparacia Pediatrycznych Badań Klinicznych
Warsaw, 04-730, Poland
-
John Hopkins Medicine
Baltimore, Maryland, 21287, United States
-
Karolinska University hospital, Astrid Lindgrens Children Hospital
Stockholm, S-171 76, Sweden
-
PTC Clinical Site
Multiple Locations, Japan
-
Pediatric Genetics Clinic (Main MGH Hospital)
Boston, Massachusetts, 02114-2696, United States
-
Seattle Children's hospital
Seattle, Washington, 98105, United States
-
Stanford University
Stanford, California, 94305, United States
-
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, NE1 4LP, United Kingdom
-
U.O.C. Malattie Muscolari e Neurodegenerative, Dipartimento di Scienze Neurologiche e Psichiatriche, Ospedale Pediatrico Bambino Gesù
Roma, 00165, Italy
-
UOC Neuropsichiatria Infantile, Istituto Neurologico Carlo Besta-Fondazione IRCCS
Milan, 20133, Italy
-
University of California
San Diego, California, 92123, United States
-
University of Texas Health Science
Houston, Texas, 77030, United States
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.